The Ambient Light Multiple Myeloma Study

ID#: NCT05737732

Age: 21 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: February 01, 2023

End Date: June 01, 2027

Contact Information:
Barbara Plitnick, BSN
518 242-4603
Mariana Figueiro, PhD

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.


Inclusion Criteria:

- Multiple Myeloma diagnosis

- Scheduled to undergo their first Autologous Stem Cell Transplant procedure.

- 21years or older

- Able to provide informed consent.

- English-language proficient

Exclusion Criteria:

- Previous Autologous Stem Cell Transplant procedure

- Pregnancy

- Eye diseases which limit the ability of light to be processed

- Secondary cancer diagnosis within the last 5 years

- Severe sleep disorders

- History of bipolar disorder or manic episodes

- Severe psychological impairment

- Previous use of light therapy

- Active infection including COVID-19 infection